Literature DB >> 13129413

Cost-effectiveness league tables: valuable guidance for decision makers?

Josephine Mauskopf1, Frans Rutten, Warren Schonfeld.   

Abstract

This paper asks the question 'are cost-effectiveness league tables a good way to provide information to decision makers about the value of new healthcare interventions?' League tables that rank alternative healthcare interventions based on their incremental cost-effectiveness ratios (ICERs) are seen by economists as a valuable tool to inform decision makers about the allocation of scarce healthcare resources. However, league tables frequently compare ICERs from studies that have computed these ratios using different methods and assumptions including choice of comparator, choice of discount rate, time horizon, and population subgroup. The methodological differences among studies may influence the ranking of the studies and therefore decisions made using the league table. In addition, league tables generally do not include measures of the uncertainty of the cost-effectiveness estimates. In this paper, a reference case approach is proposed for the computation of the incremental cost-effectiveness ratio and an expanded set of measures is proposed for inclusion in the league table. In addition, a central repository for reference case expanded league tables is suggested so that decision makers can use them more effectively and more consistently.

Mesh:

Year:  2003        PMID: 13129413     DOI: 10.2165/00019053-200321140-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  23 in total

1.  Opportunity costs and uncertainty in the economic evaluation of health care interventions.

Authors:  P Sendi; A Gafni; S Birch
Journal:  Health Econ       Date:  2002-01       Impact factor: 3.046

2.  Stochastic league tables: communicating cost-effectiveness results to decision-makers.

Authors:  R C Hutubessy; R M Baltussen; D B Evans; J J Barendregt; C J Murray
Journal:  Health Econ       Date:  2001-07       Impact factor: 3.046

3.  Using cost-effectiveness league tables to compare interventions to prevent sexual transmission of HIV.

Authors:  S D Pinkerton; A P Johnson-Masotti; D R Holtgrave; P G Farnham
Journal:  AIDS       Date:  2001-05-04       Impact factor: 4.177

4.  Meta-analysis and quality of evidence in the economic evaluation of drug trials.

Authors:  R J Simes; P P Glasziou
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

5.  The decision rules of cost-effectiveness analysis.

Authors:  G Karlsson; M Johannesson
Journal:  Pharmacoeconomics       Date:  1996-02       Impact factor: 4.981

6.  Using economic evidence in reimbursement decisions for health technologies: experience of 4 countries.

Authors:  A Harris; M Buxton; B O'Brien; F R Drummond
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2001-10       Impact factor: 2.217

7.  Economics of coronary artery bypass grafting.

Authors:  A Williams
Journal:  Br Med J (Clin Res Ed)       Date:  1985-08-03

8.  Some guidelines on the use of cost effectiveness league tables.

Authors:  J Mason; M Drummond; G Torrance
Journal:  BMJ       Date:  1993-02-27

9.  Cost-effectiveness league tables: more harm than good?

Authors:  M Drummond; G Torrance; J Mason
Journal:  Soc Sci Med       Date:  1993-07       Impact factor: 4.634

Review 10.  Maximizing the cost-effectiveness of lipid-lowering therapy.

Authors:  T A Jacobson; J R Schein; A Williamson; C M Ballantyne
Journal:  Arch Intern Med       Date:  1998-10-12
View more
  11 in total

Review 1.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  A decision-theoretic framework for the application of cost-effectiveness analysis in regulatory processes.

Authors:  Gianluca Baio; Pierluigi Russo
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

Review 3.  Principles of pharmacoeconomics and their impact on strategic imperatives of pharmaceutical research and development.

Authors:  József Bodrogi; Zoltán Kaló
Journal:  Br J Pharmacol       Date:  2010-02-02       Impact factor: 8.739

Review 4.  Economic evaluation of dialysis therapies.

Authors:  Scott W Klarenbach; Marcello Tonelli; Betty Chui; Braden J Manns
Journal:  Nat Rev Nephrol       Date:  2014-08-26       Impact factor: 28.314

5.  Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.

Authors:  Ariel Beresniak; Antonieta Medina-Lara; Jean Paul Auray; Alain De Wever; Jean-Claude Praet; Rosanna Tarricone; Aleksandra Torbica; Danielle Dupont; Michel Lamure; Gerard Duru
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

6.  Introduction to the Special Issue on "The World Health Organization Choosing Interventions That Are Cost-Effective (WHO-CHOICE) Update".

Authors:  Melanie Y Bertram; Tessa Tan Torres Edejer
Journal:  Int J Health Policy Manag       Date:  2021-11-01

7.  Developing a prioritisation framework in an English Primary Care Trust.

Authors:  Edward C F Wilson; John Rees; Richard J Fordham
Journal:  Cost Eff Resour Alloc       Date:  2006-02-17

8.  Forecasting the Incremental Value to Society Created by a Class of New Prescription Drugs: A Proposed Methodology and Its Application to Treating Chronic Hepatitis C in India.

Authors:  V Srinivasan; David E Bloom; Alex Khoury
Journal:  Appl Health Econ Health Policy       Date:  2022-03-11       Impact factor: 3.686

9.  Thresholds for the cost-effectiveness of interventions: alternative approaches.

Authors:  Elliot Marseille; Bruce Larson; Dhruv S Kazi; James G Kahn; Sydney Rosen
Journal:  Bull World Health Organ       Date:  2014-12-15       Impact factor: 9.408

Review 10.  Using Economic Evidence to Set Healthcare Priorities in Low-Income and Lower-Middle-Income Countries: A Systematic Review of Methodological Frameworks.

Authors:  Virginia Wiseman; Craig Mitton; Mary M Doyle-Waters; Tom Drake; Lesong Conteh; Anthony T Newall; Obinna Onwujekwe; Stephen Jan
Journal:  Health Econ       Date:  2016-02       Impact factor: 3.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.